Article Data

  • Views 92
  • Dowloads 0

Original Research

Open Access

Acinetobacter baumannii microbiological and phenotypic characteristics of isolates from Intensive Care Unit of the Department of Internal Medicine at the University Hospital Centre in Zagreb over a four-year period

  • DIJANA VARDA BRKIĆ1
  • ALEKSANDRA PRESEČKI STANKO1
  • SANJA PLEŠKO1
  • VESNA TRIPKOVIĆ1
  • BRANKA BEDENIĆ1,2

1Department of Clinical and Molecular Microbiology, University Hospital Centre Zagreb, Kišpatićeva 12, Zagreb, Croatia

2School of Medicine, University of Zagreb, Zagreb, Croatia

DOI: 10.22514/SV101.062015.2 Vol.10,Issue S1,June 2015 pp.13-15

Published: 22 June 2015

*Corresponding Author(s): DIJANA VARDA BRKIĆ E-mail: dijanavb098@gmail.com

PDF (122.48 kB)

Abstract


Acinetobacter baumannii is an opportun-istic nosocomial pathogen and one of the six most important multidrug-resistant microorganisms in intensive care units (ICU). 

The aim of this study was to determine the prevalence of antimicrobial resistant A. baumannii strains in ICU. 

We analysed antibiotic susceptibility of A. baumannii isolates collected in University Hospital Centre Zagreb over a four-year period (2011-2014) based on the hospital computer system data (BIS). The data were interpreted according to Clinical and Lab-oratory Standards Institute criteria.

All strains from 2014 were found to be resistant to meropenem, which is a sig-nificant increase when compared to 1.4% in 2011 and 81.8% in 2012. The resistance rate to imipenem increased to 95.8% in 2014 from 91.4% in 2011 and 81.8% in 2012. Colistin resistance, confirmed by E test, was found only in one strain in 2013. The resistance rates of other antimicrobial agents were as follows: ampicillin/sulbac-tam 8.6% and 73.9%, netilmicin 70.6% and 83.3%, gentamicin 48.6% and 91.7%, ami-kacin 82.4% and 80.0% and ciprofloxacin 100% and 100% in 2011 and 2014 respec-tively.

Our data confirmed a multidrug-resist-ance phenotype in Acinetobacter bauman-nii strains isolated in ICU at the Clinical Hospital Centre, with a significant increase in resistance rates between 2011 and 2014 against certain antimicrobial agents in-cluding ampicilin/sulbactam and carbap-enems. 

Key words

Acinetobacter baumannii, mul-tidrug resistance, extensively drug resist-ance, nosocomial pathogen

Cite And Share

DIJANA VARDA BRKIĆ,ALEKSANDRA PRESEČKI STANKO,SANJA PLEŠKO,VESNA TRIPKOVIĆ,BRANKA BEDENIĆ. Acinetobacter baumannii microbiological and phenotypic characteristics of isolates from Intensive Care Unit of the Department of Internal Medicine at the University Hospital Centre in Zagreb over a four-year period. Signa Vitae. 2015. 10(S1);13-15.

References

1. Feng Lin M, Yu Lan C. Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside. World J Clin Cases. 2014; 2(12):787-814.

2. Falagas ME, Bliziotis IA, Siempos II. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: A sys-tematic review of matched cohort and case-control studies. Crit Care. 2006;10: R48.

3. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: Multidrug-resistant Acinetobacter baumannii. Nat Rev Mi-crobiol. 2007;5:939-951.

4. Lee JC, Koerten H, van den Broek P, et al. Adherence of Acinetobacter baumannii strains to human bronchial epithelial cells. Res Microbiol. 2006;157:360.

5. Esterly J, Richardson CL, Eltoukhy NS, Qi C, Scheetz MH. Genetic Mechanisms of Antimicrobial Resistance of Acinetobacter baumannii. Ann Pharmacother. 2011.

6. Prashanth K, Badrinath S. Nosocomial infections due to Acinetobacter species: Clinical findings, risk and prognostic factors. In-dian J Med Microbiol. 2006;24:39-44.

7. Patwardhan RB, Dhakephalkar PK, Niphadkar KB, Chopade BA. A study on nosocomial pathogens in ICU with special reference to multiresistant Acinetobacter baumannii harbouring multiple plasmids. Indian J Med Res.2008;178-87.

8. Purti CT, Sunita RG, Gopal NA. Clinical and antimicrobial profile of Acinetobacter spp.: An emerging nosocomial superbug. Adv. Biomed. Res. 2014;3:13.

9. Behnia M, LoganSC, Fallen L, Catalano P. Nosocomial and ventilator-associated pneumonia in a community hospital intensive care unit: a retrospective review and analysis. BMC Research Notes. 2014;7:232

10. Gentile V, Frangipani E, Bonchi C, Minandri F, Runci F, Visca P. Iron and Acinetobacter baumannii Biofilm Formation. Pathogens. 2014;3:704-719.

11. Metan G,Pala C, Kaynar L, Cevahir F, Alp E. A nightmare for haematology clinics: extensively drug-resistant (XDR) Acinetobacter baumannii. Infez Med. 2014;1;22(4):277-82.

12. Guven T, Yilmaz G, Guner HR, Kaya Kalem A, Eser F, Tasyaran MA. Increasing resistance of nosocomial Acinetobacter bauman-nii: are we going to be defeated? Turk J Med Sci. 2014;44(1):73-8.

13. Commitee for antibiotic resistance surveillance in Croatia. Antibiotic resistance in Croatia, 2013. The Croatian Academy of Medi-cal Science. 2014.

14. Sheng WH, Liao CH, Lauderdale TL, Ko WC, Chen YS, Liu JW et al. A multicentar study of risk factors and outcome of hospital-ized patients with infections due to carbapenem-resistant Acinetobacter baumannii. Inf J Infect Dis. 2010;14:764-769.

15. Grupper M, Sprecher H, Mashich T, Finkelstein R. Attributable mortality of nosocomial Acinetobacter bacteremia. Infect Control Hosp Epidemiol. 2007;28:293-298.

16. Franolić-Kukina I, Bedenić B, Budimir A, Herljević Z, Vraneš J, Higgins P. Clonal spread of carbapenem-resistant OXA-72 positive Acinetobacter baumannii in a Croatian university hospital. Internation Journal of Infectious Diseases 2011;15:e706- e709).

17. 1Vranić-Ladavac M, Bedenić B, Minandri F, Ištok M, Frančula-Zaninović S, Ladavac R, Visca P. Carbapenem-resistance and acquired class D carbapenemases in Acinetobacter baumannii from Croatia 2009-2010. Eur J Clin Microbiol Infect Dis 2014; 33(3):471-8.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) The Science Citation Index (SCI) is a citation index originally produced by the Institute for Scientific Information (ISI) and created by Eugene Garfield. It (Science Citation Index Expanded) covers more than 8,500 notable and significant journals, across 150 disciplines in science and technology, from 1900 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.

IndexCopernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.

Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.

Scopus Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.

Submission Turnaround Time

Conferences

    Top